Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05657990

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

This is a feasibility study looking at whether the use of Tamsulosin could lower the high incidence of postoperative urinary retention (POUR) in older men who undergo an oncological thoracic surgical procedure for suspected or confirmed cancer. In addition, the study will try to identify the time of resumption of presurgical urinary function post Tamsulosin administration.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Urinary Retention Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Urination Disorders Urogenital Diseases Urologic Diseases

Age range

55 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Early Phase 1

Primary location

Ocean University Medical Center, Brick, New Jersey, United States

Loading trial locations.

About this study

Post-operative urinary retention (POUR) is a significant problem in post-operative patients. The incidence varies, but can reach up to 70%, which most commonly affects older men with enlarged prostates. Even after adjusting for the modifiable risk factors, such as decreased intraoperative foley use and post-operative narcotic use, the incidence remains high. This causes an increase in urinary tract infections, patient discomfort, longer hospital stays, and occasionally further urologic complications. Studies have shown that the use of tamsulosin, an alpha1-adrenergic receptor blocker, may decrease the incidence of POUR by improving urinary flow via relaxation of the smooth muscle tissue. Therefore, the goal of our study is to investigate whether Tamsulosin (Flomax) can be used to lower incidence of POUR in older men undergoing an oncological thoracic surgical procedure.

This is a pilot/feasibility/ early efficacy study to determine if treating men > 55 years of age with Tamsulosin prior to a thoracic oncological surgery will prevent postoperative urinary retention (POUR).

Subjects will be provided with a prescription for Tamsulosin (generic) to be taken 7 days prior to scheduled surgery. For research purposes, post-surgical spontaneous voids will be measured, and any residual urine in the bladder will be assessed and measured using a BladderScanner. This data will be used to determine postoperative urinary retention (POUR). Additionally, standard of care bladder management will be used if the subject did not spontaneously void or had excess urine residual. The algorithm in the table below will guide bladder management decisions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males
  • ≥55 years old
  • Planned thoracic oncological surgical procedure of a video assisted oncological surgical procedure for suspected or confirmed cancer.
  • Surgery scheduled more than 7 days from the time of consent

Exclusion criteria

  • Using Tamsulosin already
  • Known allergy to Tamsulosin or sulfa drugs
  • Current use of Boceprevir
  • Resting systolic blood pressure <100
  • Orthostatic hypotension of >20mm Hg systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent
  • Known history of hypotension
  • Known diagnosis of congestive heart failure (CHF) and valvular heart disease
  • History of prior prostate surgery (prostatectomy, trans-urethral resection)

Treatment and study plan

Tamsulosin

Drug

Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.

Other names: Flomax

Primary outcomes

  1. Number of participants that were able to spontaneously void after surgery completion

    Time frame: 6-8 hours post operative

    Self-reported void within 6-8 hours post operative

  2. Time of the void

    Time frame: Within 24 hours post operative

    Time (number of minutes) to first postoperative spontaneous urination post operation

  3. Volume of urine

    Time frame: Within 24 hours post operative

    Volume of urine during the first postoperative spontaneous urination post operation.

  4. Amount of residual urine

    Time frame: Within 24 hours post operative

    Patients will receive a bladder scan post their first postoperative spontaneous urination and the amount of residual urine will be measured.

  5. Number of participants that needed an intervention due to failure to spontaneously urinate

    Time frame: Within 24 hours post operative

    Patients that did not spontaneously urinate within 6-8 hours post operative will have an intervention. Potential interventions include : a) Prompted voiding and rescanning in 2 hours; b) Intermittent catheterization and patient prompting; c) Indwelling catheter inserted.

Study contacts

Contact information is provided by the study sponsor or research team.

Denise Theiler, RN

CONTACT

[email protected]

7327763301

Sponsors and collaborators

Lead sponsor

Hackensack Meridian Health

Other

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Dec 20, 2022
Registry last updated
Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.